Terms: = Brain cancer AND WT1, WAGR, 7490, ENSG00000184937, WT33, GUD, WIT-2 AND Prognosis
11 results:
1. Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy.
Cao W; Lan J; Hu C; Kong J; Xiang L; Zhang Z; Sun Y; Zeng Z; Lei S
Aging (Albany NY); 2024 Mar; 16(6):5618-5633. PubMed ID: 38499392
[TBL] [Abstract] [Full Text] [Related]
2. An immune signature to predict the prognosis of
Cao W; Sun P; Luo S; Zeng Z; Xiao C; Yu W; Lei S
Aging (Albany NY); 2023 Oct; 15(19):10453-10472. PubMed ID: 37812190
[TBL] [Abstract] [Full Text] [Related]
3. Maintenance of wt1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with wt1 peptide vaccine immunotherapy.
Yokota C; Kagawa N; Takano K; Chiba Y; Kinoshita M; Kijima N; Oji Y; Oka Y; Sugiyama H; Tsuboi A; Izumoto S; Kishima H; Hashimoto N
Cancer Immunol Immunother; 2022 Jan; 71(1):189-201. PubMed ID: 34089373
[TBL] [Abstract] [Full Text] [Related]
4. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
[TBL] [Abstract] [Full Text] [Related]
5. Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue.
Zhou Q; Andersson R; Hu D; Bauden M; Kristl T; Sasor A; Pawłowski K; Pla I; Hilmersson KS; Zhou M; Lu F; Marko-Varga G; Ansari D
EBioMedicine; 2019 May; 43():282-294. PubMed ID: 30982764
[TBL] [Abstract] [Full Text] [Related]
6. Identifying the role of Wilms tumor 1 associated protein in cancer prediction using integrative genomic analyses.
Wu LS; Qian JY; Wang M; Yang H
Mol Med Rep; 2016 Sep; 14(3):2823-31. PubMed ID: 27430156
[TBL] [Abstract] [Full Text] [Related]
7. Atypical teratoid/ rhabdoid tumor, an immunohistochemical study of potential diagnostic and prognostic markers.
Al-Hussaini M; Dissi N; Souki C; Amayiri N
Neuropathology; 2016 Feb; 36(1):17-26. PubMed ID: 26207291
[TBL] [Abstract] [Full Text] [Related]
8. α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.
Akiyama Y; Oshita C; Kume A; Iizuka A; Miyata H; Komiyama M; Ashizawa T; Yagoto M; Abe Y; Mitsuya K; Watanabe R; Sugino T; Yamaguchi K; Nakasu Y
BMC Cancer; 2012 Dec; 12():623. PubMed ID: 23270484
[TBL] [Abstract] [Full Text] [Related]
9. Use of (11)C-methionine PET parametric response map for monitoring wt1 immunotherapy response in recurrent malignant glioma.
Chiba Y; Kinoshita M; Okita Y; Tsuboi A; Isohashi K; Kagawa N; Fujimoto Y; Oji Y; Oka Y; Shimosegawa E; Morita S; Hatazawa J; Sugiyama H; Hashimoto N; Yoshimine T
J Neurosurg; 2012 Apr; 116(4):835-42. PubMed ID: 22242671
[TBL] [Abstract] [Full Text] [Related]
10. Integrative genomic analyses on interferon-lambdas and their roles in cancer prediction.
Yang L; Wei J; He S
Int J Mol Med; 2010 Feb; 25(2):299-304. PubMed ID: 20043142
[TBL] [Abstract] [Full Text] [Related]
11. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma.
Yu J; Zhang H; Gu J; Lin S; Li J; Lu W; Wang Y; Zhu J
BMC Cancer; 2004 Sep; 4():65. PubMed ID: 15367334
[TBL] [Abstract] [Full Text] [Related]
